Canagliflozin for fluid removal and health in peritoneal dialysis patients
Treatments studied
Part of Digestive system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if canagliflozin, a diabetes medicine, helps remove extra fluid and reduce scarring in people on peritoneal dialysis (home-based dialysis). It may improve your dialysis results and protect your belly lining.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be on peritoneal dialysis (also called PD) for at least 3 months using dextrose-based solutions.
- You should have a specific type of membrane transport (high or high-average) from a test called PET.
- You cannot have had a recent infection in your belly or tunnel (where the dialysis tube goes in).
- You cannot have severe liver disease or have a kidney transplant planned in the next 6 months.
- You cannot be pregnant or breastfeeding, and you should not have a history of serious side effects from canagliflozin.
- You must not be taking certain medicines like digoxin, phenobarbital, phenytoin, rifampin, or ritonavir unless they can be safely stopped.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if canagliflozin, a diabetes medication, can help people with very advanced kidney disease or who recently started dialysis. It uses MRI scans to see how the drug affects the heart and kidneys.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This trial tests whether empagliflozin, a medication originally for diabetes, can help protect the remaining kidney function in people who have just started peritoneal dialysis. If you started dialysis within the last 3 months and still make some urine, this study may be a good fit.
This study tests a diabetes medication called canagliflozin in people who receive dialysis treatment for kidney disease. Researchers want to see if it's safe and how it works in patients whose kidneys no longer function on their own.
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
This study tests whether a type of diabetes medicine called SGLT2 inhibitors (which help lower blood sugar and protect the kidneys) can benefit people who are on chronic peritoneal dialysis. You may be able to join if you are 13 or older, have some urine output, and do not have certain other health issues.
Hear when a new ESRD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.